5033-28-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-N'-hydroxybenzenecarboximidamide is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Chemical Synthesis:
In the field of organic chemistry, 4-chloro-N'-hydroxybenzenecarboximidamide serves as a versatile building block for the synthesis of a wide range of chemical compounds. Its reactivity and functional groups make it a valuable precursor for creating complex molecules with diverse applications.
Used in Research and Development:
Due to its unique chemical structure, 4-chloro-N'-hydroxybenzenecarboximidamide is utilized in research and development for studying various chemical reactions and exploring new synthetic pathways. It can be used to investigate the properties of related compounds and to develop new methodologies in organic synthesis.
Specific Application:
4-Chloro-N'-hydroxybenzenecarboximidamide is used to synthesize O-(3-piperidino-2-hydroxy-1-propyl)-4-chloro-benzamidoxime dihydrochloride, which is a compound with potential applications in various fields, such as pharmaceuticals or chemical research. The synthesis of 4-CHLORO-N'-HYDROXYBENZENECARBOXIMIDAMIDE demonstrates the utility of 4-chloro-N'-hydroxybenzenecarboximidamide as a starting material for the development of new and innovative products.

Upstream product

• 68451-72-9 (Z)-O-Benzoyl-4-chlorbenzamidoxim 
• 68451-85-4 C₁₄H₁₀Cl₂N₂O₂ 
• 68451-91-2 C₁₄H₁₀ClN₃O₄ 
• 68451-78-5 C₁₅H₁₃ClN₂O₃ 
• 125338-28-5 3-(4-Chloro-phenyl)-5-{(E)-2-[3-(4-chloro-phenyl)-isoxazol-4-yl]-vinyl}-4,5-dihydro-[1,2,4]oxadiazole 
• 623-03-0 4-Cyanochlorobenzene 
• 503027-47-2 N,N'-bis(trimethylsilyl)sulfurdiimide 
• 15500-74-0 4-chlorobenzonitrile N-oxide 
• 172469-60-2 4-(4-Chloro-phenyl)-2λ⁴-[1,2,3,5]oxathiadiazol-2-ylamine 
• 28123-63-9 4-chlorobenzohydroximoyl chloride 
• 67-56-1 methanol 
• 766-84-7 3-chloro-benzonitrile 
• 140-53-4 p-chlorobenzyl cyanide 
• 3848-36-0 4-chlorobenzaldoxime 

Downstream Products

• 30149-93-0 3-<(3-p-Chlorophenyl)-1,2,4-oxadiazol-5-yl>propionic acid 
• 93474-38-5 O-Carbanilino-p-chlorobenzamidoxime 
• 13273-57-9 3-(4-chlorophenyl)-5-phenyl-1,2,4-oxadiazole 
• 52596-85-7 3-(4-chloro)phenyl-5-(4-methyl)phenyl-[1,2,4]oxadiazole 
• 158042-17-2 3,5-bis(4-chlorophenyl)-1,2,4-oxadiazole 
• 57238-75-2 5-(chloromethyl)-3-(4-chlorophenyl)-1,2,4-oxadiazole 

Relevant academic research and scientific papers

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

Design and synthesis of new triarylimidazole derivatives as dual inhibitors of BRAFV600E/p38α with potential antiproliferative activity

Recent studies have shown that combining kinase inhibitors has additive and synergistic effects. BRAFV600E and p38α have been extensively studied as potential therapeutic targets for a variety of diseases. In keeping with our interest in developing multi-targeted anticancer agents, a series of novel triaryl-imidazole-based analogues containing 3-aryl-1,2,4-oxadiazoles moiety (4a-h, Scaffold B) and their reaction intermediates aryl carboximidamides moiety (3a-h, Scaffold A) have been rationally designed, synthesized, and evaluated in vitro for their antiproliferative activity as dual p38α/BRAFV600E inhibitors. The results revealed that the presence of the carboximidamide moiety is required for activity, and the best activity correlates with the Ar = 1,2-benzodioxole (3e) ≥ 4-CH3O-C6H5-(3c) > 2-naphthyl (3h) > 4-Cl-C6H5 (3b). Ring closure of carboximidamide to 1,2,4-oxadiazole significantly reduces the activity. The results of docking study into p38α revealed higher binding affinities for compounds 3c, 3e, and 3h compared to the co-crystallized ligand, SB2. However, the docking study of compounds 3c and 3e into BRAFV600E revealed slightly lower affinities than vemurafenib.

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.

Novel 1,2,4-oxadiazole derivatives as selective butyrylcholinesterase inhibitors: Design, synthesis, and biological evaluation

Alzheimer’s disease (AD) is a progressive mental disorder that brings a huge economic burden to the healthcare systems. During this illness, acetylcholine levels in the cholinergic systems gradually diminish, which results in severe memory loss and cognitive impairments. Moreover, Butyrylcholinesterase (BuChE) enzyme participates in cholinergic neurotransmission regulation by playing a prominent role in the latter phase of AD. In this study, based on donepezil, which is an effective acetylcholinesterase (AChE) inhibitor, a series of 1,2,4-oxadiazole compounds were designed, synthesized and their inhibitory activities towards AChE and BuChE enzymes were evaluated. Some structures exhibited a higher selectivity rate towards BuChE in comparison to donepezil. Notably, compound 6n with an IC50 value of 5.07 μM and an SI ratio greater than 19.72 showed the highest potency and selectivity towards BuChE enzyme. The docking result revealed that compound 6n properly fitted the active site pocket of BuChE enzyme, and formed desirable lipophilic interactions and hydrogen bonds. Moreover, according to in silico ADME studies, these compounds have proper potential for being developed as new oral anti-Alzheimer’s agents.

Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study

New antibacterial drugs are urgently needed to tackle the rapid rise in multi-drug resistant bacteria. DNA gyrase is a validated target for the development of new antibacterial drugs. Thus, in the present investigation, a novel series of 1,2,4-oxadiazole-

Novel chalcone/aryl carboximidamide hybrids as potent anti-inflammatory via inhibition of prostaglandin E2 and inducible NO synthase activities: design, synthesis, molecular docking studies and ADMET prediction

Two series of chalcone/aryl carboximidamide hybrids 4a–f and 6a–f were synthesised and evaluated for their inhibitory activity against iNOS and PGE2. The most potent derivatives were further checked for their in?vivo anti-inflammatory activity utilising carrageenan-induced rat paw oedema model. Compounds 4c, 4d, 6c and 6d were proved to be the most effective inhibitors of PGE2, LPS-induced NO production, iNOS activity. Moreover, 4c, 4d, 6c and 6d showed significant oedema inhibition ranging from 62.21% to 78.51%, compared to indomethacin (56.27 ± 2.14%) and celecoxib (12.32%). Additionally, 4c, 6a and 6e displayed good COX2 inhibitory activity while 4c, 6a and 6c exhibited the highest 5LOX inhibitory activity. Compounds 4c, 4d, 6c and 6d fit nicely into the pocket of iNOS protein (PDB ID: 1r35) via the important amino acid residues. Prediction of physicochemical parameters exhibited that 4c, 4d, 6c and 6d had acceptable physicochemical parameters and drug-likeness. The results indicated that chalcone/aryl carboximidamides 4c, 4d, 6c and 6d, in particular 4d and 6d, could be used as promising lead candidates as potent anti-inflammatory agents.

Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-containing pyrazolo[3,4-b]pyridinones as a new series of AMPKɑ1β1γ1 activators

Adenosine monophosphate-activated protein kinase (AMPK) plays a key role in maintaining whole-body homeostasis and has been regarded as a therapeutic target for the treatment of diabetic nephropathy (DN). Herein, a series of 1,2,4-oxadiazole-containing py

One-pot synthesis of 1,2,4-oxadiazoles from chalcogen amino acid derivatives under microwave irradiation

A series of sulfur- and selenium-bearing, amino acid-derived 1,2,4-oxadiazoles were obtained by a simple procedure. The method consists of EDC-promoted coupling of chalcogen amino acid derivatives with arylamidoximes in acetone, followed by solvent removal and microwave irradiation in water medium. Influence of amidoxime substituents, of the chalcogen atom and of the amino acid side chain is discussed. The results showed this to be a fast, easy and effective method to obtain these compounds, with good functional-group tolerance, potentially favouring future applications in organic synthesis.

Catalyst-free, one-pot strategy to access 3-substituted-5-amino-1,2,4-thiadiazoles in water

A protocol has been devised for the synthesis of 3-substituted 5-amino-1,2,4-thiadiazoles utilizing isothiocyanates, amidoximes and water as an eco-friendly solvent. The strategy involves consecutive C?N and S?N bonds formation in a one-pot reaction under

Imidazole hydrochloride promoted synthesis of 3,5-disubstituted-1,2,4-oxadiazoles

Imidazole hydrochloride as an additive promotes the reaction of amidoximes and DMA derivatives to generated 3,5-disubstituted-1,2,4-oxadiazoles in low to excellent yields without the use of coupling reagents, oxidants, strong acids or bases and other additives.